Regulus Therapeutics Inc. (NASDAQ:RGLS)’s share price shot up 4.4% on Friday . The stock traded as high as $3.37 and last traded at $3.32, with a volume of 272,651 shares trading hands. The stock had previously closed at $3.18.

Several brokerages have weighed in on RGLS. Zacks Investment Research upgraded Regulus Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 6th. FBR & Co restated an “outperform” rating and set a $9.00 price objective (down from $30.00) on shares of Regulus Therapeutics in a research note on Tuesday, June 28th. Wedbush restated an “outperform” rating and set a $15.00 price objective (down from $35.00) on shares of Regulus Therapeutics in a research note on Tuesday, June 28th. Needham & Company LLC dropped their price objective on Regulus Therapeutics from $25.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, June 28th. Finally, BMO Capital Markets cut Regulus Therapeutics from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $16.00 to $4.00 in a research note on Tuesday, June 28th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $10.42.

The firm’s market cap is $178.93 million. The company has a 50 day moving average price of $4.71 and a 200-day moving average price of $6.14.

Regulus Therapeutics (NASDAQ:RGLS) last announced its earnings results on Monday, May 2nd. The biopharmaceutical company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by $0.07. On average, equities analysts predict that Regulus Therapeutics Inc. will post ($1.54) earnings per share for the current fiscal year.

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.